Bortezomib, free base, 100mg
To Order Contact us: lieven@wlsolutions.be
Bortezomib |
||
| GP0262-25 | 25 | EUR 216.3 |
Bortezomib |
||
| GP0262-5 | 5 | EUR 98.4 |
Bortezomib, 99% |
||
| BC010-005 | 5mg | Ask for price |
Bortezomib, 99% |
||
| BC010-010 | 10mg | EUR 213.6 |
Bortezomib, 99% |
||
| BC010-025 | 25mg | EUR 264 |
Bortezomib, 99% |
||
| BC010-050 | 50mg | EUR 327.6 |
Bortezomib, 99% |
||
| BC010-500 | 500mg | EUR 724.8 |
Bortezomib (PS-341) |
||
| A2614-10 | 10 mg | EUR 142.8 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (PS-341) |
||
| A2614-100 | 100 mg | EUR 408 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (PS-341) |
||
| A2614-25 | 25 mg | EUR 208.8 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (PS-341) |
||
| A2614-5.1 | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (PS-341) |
||
| A2614-500 | 500 mg | EUR 1005.6 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (PS-341) |
||
| A2614-S | Evaluation Sample | EUR 97.2 |
|
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
||
Bortezomib (BTZ) Protein (BSA) |
||
| 20-abx651876 |
|
|
Bortezomib (BTZ) Protein (OVA) |
||
| 20-abx651877 |
|
|
BSA Conjugated Bortezomib (BTZ) |
||
| 4-CPK684Ge11 |
|
|
|
Description: Recombinant Pan-species Bortezomib expressed in: E.coli |
||
OVA Conjugated Bortezomib (BTZ) |
||
| 4-CPK684Ge21 |
|
|
|
Description: Recombinant Pan-species Bortezomib expressed in: E.coli |
||
Bortezomib (Proteasome inhibitor) |
||
| SIH-328-25MG | 25 mg | EUR 192 |
|
Description: The substance Bortezomib is a proteasome inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white powder which is soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol. |
||
Bortezomib (Proteasome inhibitor) |
||
| SIH-328-5MG | 5 mg | EUR 138 |
|
Description: The substance Bortezomib is a proteasome inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white powder which is soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol. |
||
Biotin-X, free acid:100mg |
||
| 90053 | 100MG | EUR 158.4 |
|
Description: Minimum order quantity: 1 unit of 100MG |
||
Bioin-XX, free acid: (100mg) |
||
| 90054 | 100MG | EUR 258 |
|
Description: Minimum order quantity: 1 unit of 100MG |
||
TMB free base |
||
| TB0954 | 1g | EUR 85.06 |
FIPI (free base) |
||
| B2372-25 | each | EUR 757.2 |
FIPI (free base) |
||
| B2372-5 | each | EUR 235.2 |
THZ1 (Free base) |
||
| 9664-25 | each | EUR 1227.6 |
THZ1 (Free base) |
||
| 9664-5 | each | EUR 352.8 |
R406 (free base) |
||
| A5880-100 | 100 mg | EUR 1452 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-25 | 25 mg | EUR 616.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5 | 5 mg | EUR 199.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5.1 | 10 mM (in 1mL DMSO) | EUR 316.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-S | Evaluation Sample | EUR 97.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406(free base) |
||
| E1KS1533 | 2mg | EUR 625.2 |
R406 (free base) |
||
| HY-11108 | 10mM/1mL | EUR 277.2 |
YM158 (free base) |
||
| HY-U00355 | 1mg | EUR 2770.8 |
MCC950 (Free base) |
||
| B1031-1 | each | EUR 183.6 |
MCC950 (Free base) |
||
| B1031-5 | each | EUR 548.4 |
ITI214 (free base) |
||
| HY-12501 | 100mg | EUR 3531.6 |
PLX5622 (free base) |
||
| B2965-25 | 25 mg | EUR 903.6 |
PLX5622 (free base) |
||
| B2965-5 | 5 mg | EUR 272.4 |
AZD4547, Free Base |
||
| ADC-P-063 | unit | Ask for price |
AZD8055, Free Base |
||
| ADC-P-064 | unit | Ask for price |
AZD3839 (free base) |
||
| HY-13438 | 50mg | EUR 1216.8 |
Apatinib (Free base) |
||
| B1613-25 | each | EUR 496.8 |
Apatinib (Free base) |
||
| B1613-5 | each | EUR 170.4 |
Imatinib, Free base |
||
| 2141-100 | each | EUR 176.4 |
Imatinib, Free base |
||
| 2141-1000 | each | EUR 502.8 |
FR167344 free base |
||
| HY-100301 | 1mg | EUR 3164.4 |
FR183998 free base |
||
| HY-100302 | 1mg | EUR 1352.4 |
FR194738 free base |
||
| HY-100303 | 1mg | EUR 2388 |
Xylazine (free base) |
||
| Q-1445.0025 | 25.0g | EUR 385.2 |
|
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7] |
||
Lapatinib, Free base |
||
| 2138-100 | each | EUR 464.4 |
Lapatinib, Free base |
||
| 2138-25 | each | EUR 229.2 |
Erlotinib, Free Base |
||
| 2048-100 | each | EUR 189.6 |
Erlotinib, Free Base |
||
| 2048-1000 | each | EUR 464.4 |
Sunitinib, Free base |
||
| 2097-100 | each | EUR 229.2 |
Sunitinib, Free base |
||
| 2097-1000 | each | EUR 601.2 |
Sunitinib, Free base |
||
| 2097-25 | each | EUR 138 |
Vatalanib, Free Base |
||
| 2026-25 | each | EUR 366 |
Vatalanib, Free Base |
||
| 2026-5 | each | EUR 151.2 |
LY2835219 free base |
||
| A3575-100 | 100 mg | EUR 686.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-25 | 25 mg | EUR 309.6 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-5 | 5 mg | EUR 170.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
Carubicin (Free base) |
||
| B1853-1 | each | EUR 183.6 |
Carubicin (Free base) |
||
| B1853-5 | each | EUR 548.4 |
Rucaparib (free base) |
||
| A8893-10 | 10 mg | EUR 240 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-200 | 200 mg | EUR 1243.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5 | 5 mg | EUR 164.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5.1 | 10 mM (in 1mL DMSO) | EUR 170.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-50 | 50 mg | EUR 547.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
RPR107393 free base |
||
| HY-100299 | 1mg | EUR 577.2 |
Vatalanib (free base) |
||
| HY-10203 | 5mg | EUR 142.8 |
Ripasudil free base |
||
| HY-15685A | 10mg | EUR 489.6 |
AS2863619 (free base) |
||
| HY-126675 | 5mg | EUR 1410 |
Linsitinib, Free base |
||
| 2294-25 | each | EUR 679.2 |
Linsitinib, Free base |
||
| 2294-5 | each | EUR 222 |
Tipifarnib, Free base |
||
| 2296-1 | each | EUR 170.4 |
Tipifarnib, Free base |
||
| 2296-5 | each | EUR 496.8 |
Nintedanib (free base) |
||
| GW5215-100 | 100 | EUR 274.7 |
Nintedanib (free base) |
||
| GW5215-25 | 25 | EUR 117.8 |
Terbinafine (Free base) |
||
| B2423-250 | each | EUR 248.4 |
Terbinafine (Free base) |
||
| B2423-50 | each | EUR 144 |
Ruxolitinib (free base) |
||
| 10-042 | 25 mg | EUR 418.2 |
|
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). |
||